Strong and qualified partners

Experienced industry experts and practitioners are supporting Formycon with words and deeds. They essentially contribute in developing biosimilars on highest levels.

.

Dr. Gerhard Schaefer

Gerhard Schaefer graduated with a Ph.D. in Chemistry from Stuttgart University. During his more than 30 years in the generic pharmaceutical industry, he held increasing senior management positions in development, quality assurance / control and business development at Azupharma, Knoll, Stada, HEXAL and Sandoz. Among his numerous responsibilities, he was appointed to Head of Development and Business Development at HEXAL in 2001 and at the same time became Member of the Board of Executive Directors of HEXAL AG. Since the acquisition of HEXAL AG by Novartis / Sandoz in 2005 and until February 2012, he was Managing Director at Sandoz International and Head of Global Product Development and Global Business Development at Sandoz, the second largest generic pharmaceutical company, where he was managing eleven development centers worldwide.

Dr. Bernhard Hampl

Over the past 20 years, Dr. Bernhard Hampl, who has a doctorate in the field of pharmaceutical chemistry, was a successful CEO in large American generics companies such as EON LABS Inc. and later Sandoz US, which after fusion of the two companies became America’s second-largest manufacturer of generics. Dr. Hampl, who started his career at the German subsidiary of American Cyanamid / Lederle in Wolfratshausen near Munich, has been living in Connecticut/USA for the past 20 years and brings wide-ranging international experience to Formycon. Today, he advises companies from the field of pharmaceuticals and biotechnology as well as investment companies.

Prof. Dr. Johannes Buchner

After studying Biology and receiving his PhD from the University of Regensburg in 1991, Prof. Buchner investigated new concepts in cancer treatment during his postdoctoral stay at the National Institutes of Health in Bethesda, USA. He returned to the University of Regensburg as a group leader, and since 1998 he is a Professor for Biotechnology at the Technical University of Munich, Germany. His research focuses on chaperone proteins and antibodies. Prof. Buchner is a member of the German Academy of Sciences (Leopoldina) as well as the Bavarian Academy of Sciences and Humanities. He has received numerous awards for his research, including the Hans Neurath Award from the Protein Society and the Schleiden Medal awarded by Leopoldina.

Thomas Siklosi

Thomas Siklosi is a renowned biotech manager and expert in the development and production of biologics and biosimilars. He gained his early professional experience in the field of biotechnology at Boehringer Mannheim. In 1984, he moved to the biotech pioneer Rentschler Arzneimittel and held various roles in the development and production of interferons, later being responsible at Rentschler Biotechnologie for biopharmaceutical substances. In cooperation with a leading generic manufacturer, he was responsible as project manager for the technical development of the complex glycoprotein erythropoetin, which received approval as the first epoetin-alfa biosimilar in the EU in 2007. In September 2012, Siklosi was appointed to the Board of Management at Rentschler Biopharma SE. Siklosi is a Member of the University Council of Biberach University and owns numerous patents in the field of biotechnology.